Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Sunho Biologics,Inc. ( (HK:2898) ) is now available.
Sunho Biologics, Inc. has announced an updated composition of its board of directors, effective February 28, 2026, detailing the appointments of executive, non-executive, and independent non-executive directors. The company has also clarified the structure of its three key board committees, assigning chairmanships and memberships across the audit, remuneration, and nomination committees, which is expected to strengthen corporate governance and oversight for shareholders.
Executive directors now include Zhang Feng and Jiang Xiaoling, with Fan Rongkui serving as a non-executive director, and Chan Heung Wing Anthony, Feng Lan, and Shi Luwen acting as independent non-executive directors. Committee leadership has been allocated with Chan chairing the audit committee, Feng leading both the remuneration and nomination committees, and Zhang chairing the nomination committee, signaling a defined governance framework as Sunho Biologics continues its operations in the Hong Kong market.
The most recent analyst rating on (HK:2898) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.
More about Sunho Biologics,Inc.
Sunho Biologics, Inc., incorporated in the Cayman Islands and listed in Hong Kong under stock code 2898, operates in the biotechnology and biopharmaceutical industry. The company focuses on developing and commercializing biological therapies, positioning itself within the broader life sciences and healthcare market.
Average Trading Volume: 9,179
Technical Sentiment Signal: Hold
Current Market Cap: HK$935.5M
For an in-depth examination of 2898 stock, go to TipRanks’ Overview page.